<DOC>
	<DOCNO>NCT02550119</DOCNO>
	<brief_summary>This randomize pilot clinical trial dolasetron mesylate dexamethasone without aprepitant prevent nausea vomit patient undergo oxaliplatin-containing chemotherapy gastrointestinal malignancy . Antiemetic drug may help lessen prevent nausea vomit patient treated chemotherapy . It yet know whether give aprepitant together dolasetron mesylate dexamethasone effective dolasetron mesylate dexamethasone alone prevent nausea vomiting .</brief_summary>
	<brief_title>Dolasetron Mesylate Dexamethasone With Without Aprepitant Preventing Nausea Vomiting Patients Undergoing Oxaliplatin-Containing Chemotherapy Gastrointestinal Malignancy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate incidence severity acute delay nausea vomit associate oxaliplatin-containing regimen patient gastrointestinal ( GI ) malignancy . II . To estimate percent patient experience nausea vomit first second cycle oxaliplatin-containing regimen , would consent randomization standard antiemetic therapy without aprepitant . III . To obtain preliminary data safety efficacy aprepitant , combination dolasetron ( dolasetron mesylate ) dexamethasone , patient receive oxaliplatin-containing regimen . IV . To report medication compliance antiemetic medication ( dexamethasone aprepitant placebo ) schedule take home day 2 3 randomized patient ( day 1 = day treatment ) . OUTLINE : Patients receive standard antiemetic comprise dolasetron mesylate orally ( PO ) intravenously ( IV ) dexamethasone PO IV course 1 oxaliplatin-containing chemotherapy . Patients experience grade 1-4 nausea vomiting* randomize 1 2 treatment arm . ARM I : Patients receive dolasetron mesylate PO IV , dexamethasone PO IV , aprepitant PO 1 day chemotherapy dexamethasone PO aprepitant PO day 2 3 chemotherapy begin course 2-3 . ARM II : Patients receive dolasetron mesylate dexamethasone Arm I placebo PO 1 day chemotherapy dexamethasone PO placebo PO day 2 3 chemotherapy begin course 2-3 . In arm , treatment continue absence unacceptable toxicity . NOTE : * Patients develop nausea vomit second course treatment also randomize course 3 4 chemotherapy . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dolasetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients diagnosis GI malignancy schedule receive initial treatment oxaliplatincontaining regimen combination 5fluorouracil ; include combination fluorouracil , oxaliplatin , leucovorin calcium ( FOLFOX ) , FOLFOX + bevacizumab , FOLFOX + cetuximab Standard antiemetic therapy initial treatment must include dolasetron dexamethasone ; minimum adequate dos include either : Dolasetron ( Anzemet ) 100mg PO/IV 1.8mg/kg IV AND Dexamethasone ( Decadron ) 10mg PO/IV Patient must agree , part inform consent , keep journal episode nausea , vomit , retch , amount rescue medication use day 1 5 ( day 1 = day treatment ) Signed informed consent Allergy intolerance dolasetron dexamethasone Use another antiemetic agent ( 5HT3 antagonist , phenothiazine , butyrophenones , cannabinoids , metoclopramide , corticosteroid ) within 72 hour day 1 study An episode vomit retch within 24 hour start initial treatment oxaliplatincontaining regimen Severe concurrent illness neoplasia Gastrointestinal obstruction active peptic ulcer Radiation therapy abdomen pelvis within 1 week day 1 study Absolute neutrophil count le 1.5 x 10^9/L ( unless physician approves proceed chemotherapy ) Platelets less 100 x 109/L ( unless physician approves proceed chemotherapy ) Total bilirubin &gt; 2 x upper limit normal Patients pregnant breast feed Patients nonEnglish speak Patients cancerinduced nausea vomit grade 1 great use Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>